| In partnership with |  |
| Good day, 360! | Here are our top investing ideas today. And don't forget to join us in Market Masters - the hottest trading room around 🔥. Be the best prepared trader on the Street! | | FOCUS LIST🔎 | ZAPP - Up over 25% in the pre-market after entering into a new standby equity purchase agreement, securing increased commitment of up To $50M to accelerate commercial rollout of i300 electric urban motorcycle | FRSX - Up over 10% in pre after securing follow-up order from leading Japanese vehicle manufacturer | IMMP - Up over 18% in pre after reporting positive results in first line head and neck Squamous Cell Carcinoma patients with negative PD-L1 expression | | 🎯Did you miss Jeff's Bullseye of the Week? | Then you missed this… | BOOM on Day #1… | | And another BOOM on Day #2… |  | *Trading is hard, results not guaranteed and should not be expected to be replicated typically. |
| Jeff is in the meat grinder with his members, making real-money trades, alerting his every move along the way. | Don't miss the next BOOM! |
|
| | HOTLIST🔥 | ZAPP - Up over 25% in the pre-market after entering into a new standby equity purchase agreement, securing increased commitment of up To $50M to accelerate commercial rollout of i300 electric urban motorcycle | Zapp Electric Vehicles Group Limited (ZAPP) designs, manufactures, and sells electric vehicles. | In the pre-market this morning, the company announced that it had entered into into a new standby equity purchase agreement with an affiliate of Yorkville Advisors Global, securing increased commitment of up To $50M to accelerate commercial rollout of i300 electric urban motorcycle. | ZAPP has been in play this week on a technical breakout, and after pulling back is up 25% this morning in reaction to the news. | | The first target for bulls is the pre-market high at $12.94. | Beyond that, $13.21, $15 and $19.14 come into play. | Below $12.94, targets to the downside are $12, $11, $10, $9.30, $9 and $8.50. | | FRSX - Up over 10% in pre after securing follow-up order from leading Japanese vehicle manufacturer | Foresight Autonomous Holdings Ltd. (FRSX) is a technology company that engages in the development of smart multi-spectral 3D vision software solutions and cellular-based applications for the automotive industry in Israel, Japan, the United States, and internationally. | In the pre-market this morning, the company announced the signing of an agreement for a follow-up paid software proof of concept (POC) project with a leading Japanese vehicle manufacturer. The software project follows the successful completion of two POC projects, as reported by the company on February 5, 2024. | The vehicle manufacturer seeks to improve existing safety features in its vehicles already equipped with level 2 and level 3 autonomous driving features. Using its own designated cameras and hardware, the vehicle manufacturer intends to conduct a comprehensive evaluation of the software capabilities of ScaleCam™ to detect objects accurately and will assess the feasibility of rapid software integration. ScaleCam is Foresight's 3D perception modular stereoscopic vision solution made up of two separate cameras. | Successful completion of the project may pave the way for a deeper collaboration with the vehicle manufacturer, potentially leading to the integration of Foresight's technology into the vehicle manufacturer's current and future mass-produced passenger vehicles. | Shares for FRSX traded up over 10% in the pre-market in reaction to the news. | | The first target for bulls is the pre-market high at $1.12. | Above that, targets to the upside are $1.15, $1.25, $1.37, $1.50 and $1.64. | Below it, targets to the downside are $1.06, $1 and then a gap fill at $0.9860 with $0.95 below that. | | IMMP - Up over 18% in pre after reporting positive results in first line head and neck Squamous Cell Carcinoma patients with negative PD-L1 expression | Immutep Limited (IMMP) is a clinical-stage biotechnology company that engages in developing novel LAG-3 Immunotherapy for cancer and autoimmune diseases. | In the after-hours yesterday, the company announces positive results from Cohort B of the TACTI-003 (KEYNOTE-PNC-34) Phase IIb trial evaluating eftilagimod alfa (efti) in combination with MSD's (Merck & Co., Inc., Rahway, NJ, USA) anti-PD-1 therapy KEYTRUDA® (pembrolizumab) as first-line treatment of recurrent or metastatic head and neck squamous cell carcinoma patients (1L HNSCC) with negative PD-L1 expression. | Highlights of the results include: | Efti in combination with KEYTRUDA® (pembrolizumab) achieved a 35.5% response rate in evaluable patients (N=31), according to RECIST 1.1, among the highest recorded for a treatment approach not containing chemotherapy in patients with CPS <1 High complete response rate of 9.7% with three patients showing a disappearance of cancer lesions post treatment Durability of responses tracks well and over 50% of patients received treatment for at least six months Combination continues to have a favorable safety profile with no new safety signals observed Based on encouraging results and high unmet medical need, the path forward will be discussed with regulatory agencies
| The stock traded up over 18% in the pre-market in reaction to the news. | | The $2.25 area acted as support in the pre-market and will be an important level to watch. | Above it, targets to the upside are $2.40, $2.60, $2.80, $3.06, and then the after-hours high of $3.40. Beyond that, $3.90, $4.40 and $5 come into play. | Below $2.25, targets to the downside are a gap fill at $2.01 and then $1.85 below that. | | | Unlock the Secret to Exceeding Your Dividend Income | Dear Trader, | Feeling the pinch of inflation? Yeah, we've all been there. Dividends just aren't cutting it anymore, huh? But don't worry, we've got a little secret up our sleeves that might just change the game for you. | Imagine this: a strategy that not only replaces your lost dividend income but actually surpasses it. Sounds too good to be true? Well, it's not! | 👉 Discover the Secret to Exceeding Your Dividend Income | Here's the scoop: | Why traditional dividend strategies are getting left in the dust Steady income growth that exceeds inflation Real-life stories of folks who've boosted their portfolios big time
| Don't let inflation rain on your parade. Take charge of your financial future and learn about a strategy that's built to thrive in today's market. | Click here to learn more and secure your financial future. | Catch you on the flip side, | Don Kaufman
Founder/CEO |
|
| | MARKET NEWS 📰 | | | Questions or concerns about our products? Email Support@360wallstreet.io © Copyright 2022, RagingBull | | DISCLAIMER: To more fully understand any Ragingbull.com, LLC ("RagingBull") subscription, website, application or other service ("Services"), please review our full disclaimer located at https://ragingbull.com/disclaimer | FOR EDUCATIONAL AND INFORMATION PURPOSES ONLY; NOT INVESTMENT ADVICE. Any RagingBull Service offered is for educational and informational purposes only and should NOT be construed as a securities-related offer or solicitation, or be relied upon as personalized investment advice. RagingBull strongly recommends you consult a licensed or registered professional before making any investment decision. | RESULTS PRESENTED NOT TYPICAL OR VERIFIED. RagingBull Services may contain information regarding the historical trading performance of RagingBull owners or employees, and/or testimonials of non-employees depicting profitability that are believed to be true based on the representations of the persons voluntarily providing the testimonial. However, subscribers' trading results have NOT been tracked or verified and past performance is not necessarily indicative of future results, and the results presented in this communication are NOT TYPICAL. Actual results will vary widely given a variety of factors such as experience, skill, risk mitigation practices, market dynamics and the amount of capital deployed. Investing in securities is speculative and carries a high degree of risk; you may lose some, all, or possibly more than your original investment. | RAGINGBULL IS NOT AN INVESTMENT ADVISOR OR REGISTERED BROKER. Neither RagingBull nor any of its owners or employees is registered as a securities broker-dealer, broker, investment advisor (IA), or IA representative with the U.S. Securities and Exchange Commission, any state securities regulatory authority, or any self-regulatory organization. Employees, owners, and other service providers of https:// ragingbull. com or RagingBull.com LLC are paid in whole or in part by commission based on their sales of Services to subscribers. | RagingBull.com, LLC shall be entitled to recover attorneys' fees, costs and disbursements. In the event that any suit or action is instituted as a result of doing business with RagingBull. com, LLC and/or its affiliates or if any suit or action is necessary to enforce or interpret these Terms of Service, RagingBull. com, LLC shall be entitled to recover attorneys' fees, costs and disbursements in addition to any other relief to which it may be entitled. | *Sponsored Content: If you purchase anything through a link in this email other than RagingBull services, you should assume that we have an affiliate relationship with the company providing the product or service that you purchase, and that we will be paid in some way. We recommend that you do your own independent research before purchasing anything. We believe in the companies we form affiliate relationships with, but please don't spend any money on these products or services unless you believe they will help you achieve your goals. | WE MAY HOLD SECURITIES DISCUSSED. RagingBull has not been paid directly or indirectly by the issuer of any security mentioned in the Services except possibly by advertisers in this email. However, Ragingbull.com, LLC, its owners, and its employees may purchase, sell, or hold long or short positions in securities of the companies mentioned in this communication. |
|
|
|
Tidak ada komentar:
Posting Komentar